Guidance warns against using 2 phthalates as drug excipient

03/27/2012 | InPharm.com

The FDA said in draft guidance that drugmakers should avoid using dibutyl phthalate and di(2-ethylhexyl) phthalate as an excipient in pharmaceutical and biologic products because they could be toxic to humans. The agency's Inactive Ingredients Database lists possible alternatives to the two phthalates.

View Full Article in:

InPharm.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC